SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: David Cathcart who wrote (716)2/20/1998 1:41:00 PM
From: seminole  Read Replies (2) of 1826
 
David

Good review of MGI 114. You have present the bottom line
reasons for owning this drug through MOGN stock. Phase II
trials and shrinking tumors will be the best early test.
I believe those of you who do not believe should wait to purchase.
Purchase the stock based upon success in the clinical trials not upon messages posted here.

Why is this drug so good? Because the tumors act as little
vacuum cleaners, they suck up the drug before it can damage
other healthy cells and organs. I have a theory that this
drug's toxicity level will be much lower for healthy patients
than for patients with tumors.

Why is this drug so good? Because its not really one drug.
Yes, MOGN is testing the one lead compound MGI 114 but there
other similar compounds (analogs) that work in the lab. Maybe
and hopefully MGI 114 is the best drug from this class of
compounds but maybe there is one better. MOGN has stable of interesting compounds all with slightly different toxicity and activity transport properties.

Why is this drug so good? It never fails in the lab. It
is always tested against other cancer drugs and it has never
been beat. And when someone like the NCI starts spending a
little money on research, we will find out more reasons why the drug is so good.

richard

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News